Preconditioning is hormesis part I: Documentation, dose-response features and mechanistic foundations

EJ Calabrese - Pharmacological Research, 2016 - Elsevier
This article provides the first extensive documentation of the dose response features of pre-
and postconditioning. Pre-and postconditioning studies with rigorous study designs, using …

The myocardial JAK/STAT pathway: from protection to failure

K Boengler, D Hilfiker-Kleiner, H Drexler… - Pharmacology & …, 2008 - Elsevier
Proteins of the interleukin-6 (IL-6) family bind to receptors in the plasma membrane.
Subsequent signal transduction involves activation of the janus kinase (JAK) and signal …

Loss of cardioprotection with ageing

K Boengler, R Schulz, G Heusch - Cardiovascular research, 2009 - academic.oup.com
Not only the prevalence, but also the mortality due to ischaemic cardiovascular disease is
higher in older than in young humans, and the demographic shift towards an ageing …

The non‐haematopoietic biological effects of erythropoietin

MO Arcasoy - British journal of haematology, 2008 - Wiley Online Library
In the haematopoietic system, the principal function of erythropoietin (Epo) is the regulation
of red blood cell production, mediated by its specific cell surface receptor (EpoR). Following …

Erythropoietin, erythropoiesis and beyond

S Chateauvieux, C Grigorakaki, F Morceau… - Biochemical …, 2011 - Elsevier
Erythropoietin (EPO) is a glycoprotein that is mainly produced in the adult kidney, and it was
initially highlighted for its action on the hematopoietic system. Moreover, EPO is also …

Protective effects of erythropoietin in cardiac ischemia: from bench to bedside

E Lipšic, RG Schoemaker, P van der Meer… - Journal of the American …, 2006 - jacc.org
Erythropoietin (EPO) is a hypoxia-induced hormone produced in the kidneys that stimulates
hematopoiesis in the bone marrow. However, recent studies have also shown important …

Erythropoietin suppresses the hepatic fibrosis caused by thioacetamide: role of the PI3K/Akt and TLR4 signaling pathways

MA Elbaset, BMSA Mohamed… - Oxidative Medicine …, 2023 - Wiley Online Library
Erythropoietin (EPO) is recognized for its function in erythropoiesis; however, its potential
antifibrotic effect against liver fibrosis remains unknown. This study examined whether EPO …

Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion

E Lipšic, P van der Meer, RH Henning… - Journal of …, 2004 - journals.lww.com
Erythropoietin (EPO) is a hormone known to stimulate hematopoiesis. However, recent
research suggests additional properties of EPO, such as protection against …

Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase

D Burger, M Lei, N Geoghegan-Morphet… - Cardiovascular …, 2006 - academic.oup.com
Abstract Objective: Erythropoietin (EPO), a cytokine best known for its ability to increase red
blood cell mass, has recently been shown to protect cardiomyocytes from apoptotic cell …

Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind …

I Ott, S Schulz, J Mehilli, S Fichtner… - Circulation …, 2010 - ahajournals.org
Background—Erythropoietin improves myocardial function in experimental models of
myocardial infarction. The aim of the present study was to determine the value of …